* Iovance Biotherapeutics Inc reported a quarterly adjusted loss of 28 cents per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -46 cents. The mean expectation of fourteen analysts for the quarter was for a loss of 30 cents per share. Wall Street expected results to range from -35 cents to -25 cents per share.
* Revenue rose 12,385.1% to $58.56 million from a year ago; analysts expected $53.81 million.
* Iovance Biotherapeutics Inc's reported EPS for the quarter was a loss of 28 cents.
* The company reported a quarterly loss of $83.54 million.
* Iovance Biotherapeutics Inc shares had risen by 29.3% this quarter and gained 49.3% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts was unchanged in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology & medical research peer group is also "buy"
Wall Street's median 12-month price target for Iovance Biotherapeutics Inc is 24.00 This summary was machine generated from LSEG data November 8 at 05:10 a.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -0.30 -0.28 Beat
Jun. 30 2024 -0.35 -0.34 Beat
Mar. 31 2024 -0.42 -0.42 Met
Dec. 31 2023 -0.43 -0.45 Missed
Comments